학술논문
The continuum of inflammation--cardiovascular risk--rheumatic disease activity: where can we step in?
Document Type
Academic Journal
Source
Journal of Hypertension Research. Jan-March 2022, Vol. 8 Issue 1, p14, 8 p.
Subject
Language
English
Abstract
Introduction Cardiovascular disease is the leading cause of death worldwide [1]. Chronic inflammatory rheumatic conditions have already been linked to a higher prevalence of cardiovascular events than the general population [...]
Chronic inflammatory rheumatic conditions like rheumatoid arthritis, spondyloarthritis, or systemic lupus erythematosus have been linked to a higher cardiovascular disease risk when compared to the general population. Apart from chronic inflammation, which plays a central role, this increased risk is a consequence of traditional risk factors, disease-related factors, or prescribed antirheumatic drugs. Medications like non-steroidal anti- inflammatory drugs or corticosteroids should be used with caution in rheumatic patients with established heart disease because of the additional risk they might bring. Patients with cardiovascular disease should be regularly monitored, having a screening performed every five years. Assessment tools include the SCORE system, which should be multiplied by 1.5 in patients with rheumatoid arthritis. Management of this patient population should include lifestyle changing and pharmacological treatments according to available guidelines, but clinicians should also focus on achieving tight control of the rheumatic disease since lower or no disease activity has been shown to decrease patients' cardiovascular disease risk. Keywords: inflammation, rheumatoid arthritis, hypertension, cardiovascular risk, systemic lupus erythematosus, atherosclerosis, spondyloarthritis.
Chronic inflammatory rheumatic conditions like rheumatoid arthritis, spondyloarthritis, or systemic lupus erythematosus have been linked to a higher cardiovascular disease risk when compared to the general population. Apart from chronic inflammation, which plays a central role, this increased risk is a consequence of traditional risk factors, disease-related factors, or prescribed antirheumatic drugs. Medications like non-steroidal anti- inflammatory drugs or corticosteroids should be used with caution in rheumatic patients with established heart disease because of the additional risk they might bring. Patients with cardiovascular disease should be regularly monitored, having a screening performed every five years. Assessment tools include the SCORE system, which should be multiplied by 1.5 in patients with rheumatoid arthritis. Management of this patient population should include lifestyle changing and pharmacological treatments according to available guidelines, but clinicians should also focus on achieving tight control of the rheumatic disease since lower or no disease activity has been shown to decrease patients' cardiovascular disease risk. Keywords: inflammation, rheumatoid arthritis, hypertension, cardiovascular risk, systemic lupus erythematosus, atherosclerosis, spondyloarthritis.